An observational study in Endometriosis, sponsored by Trio Fertility. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Trio Fertility · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.
Among the 34 studies in Endometriosis with a site in Canada, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 32nd registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18–45 · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Andrew Zakhari · Sites in Canada
Ages 18+ · Women only
University of Ottawa · Sites in Canada
Ages 18–60 · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 64 across the 23 interventional studies, 126 across the 11 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
Trio Fertility is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Trio Fertility has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Endometriosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05643131Hyivy Health IncHyivy Device as Non-hormonal Therapy in Endometriosis | 2026-12 |
| NCT05523284McMaster UniversityCombining Ultrasound and Biomarkers to Diagnose Superficial Endometriosis | 2026-12-30 |
| NCT07713797Trio FertilityBiomarkers for Endometriosis | 2027-01-01 |
| NCT07731776Université de SherbrookeImproving Access to Pelvic Health Physiotherapy for Endometriosis | 2027-03-29 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 34 studies in Endometriosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy.
The purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.
Background:
Endometriosis is a benign inflammatory disease defined by the presence of endometrial glands and stroma in areas outside the uterus[1]. It is estimated to affect 5%-15% of women of reproductive age [2] and is even more prevalent among women with chronic pelvic pain and infertility [3]. Endometriotic implants may be located anywhere within the pelvis, including the ovaries, pelvic peritoneum, rectovaginal septum, uterosacral ligaments, and cul-de sac. The pathophysiology of endometriosis still remains unclear. The etiologic mechanism most widely accepted is retrograde menstruation resulting in tubal backflow of endometrial cells into the pelvis during menses [4]. Over time, these cells may adhere to peritoneal surfaces, proliferate, and progressively grow. The amount, duration, and frequency of pelvic exposure to menstrual bleeding may also determine the severity of endometriosis [5]. At present, the diagnosis of endometriosis can only be definitively made by laparoscopy and biopsy of endometrial lesions for histologic confirmation. Since these are invasive procedures and usually performed at the late stages, there is an urgent need to identify non-invasive biomarkers to effectively indicate endometriosis especially at the early stages for better clinical management.
Rational:
Many genes and proteins have been proposed as biomarkers for diagnosis and follow up of endometriosis [6, 7], but none used at the present time is sensitive and specific enough either to diagnose endometriosis nor to determine the effectiveness of treatment of endometriosis. Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation [8]. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual [9]. Similarly, B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells [10]. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centres [11,12]. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis [13]. Together, both of these proteins (SNCG and BCL6) have been linked to endometriosis. However, their diagnostic/prognostic utility by non-invasive means such as measurement in peripheral blood and menstrual fluid of patients with endometriosis remains to be investigated.
Hypothesis:
The research team hypothesize that SNCG and BCL6 concentrations are altered in patients with endometriosis and measurements of circulating SNCG and BCL6 levels in serum/menstrual blood could be used for diagnosis and/or prognosis of endometriosis.
OBJECTIVES
Objectives:
The aim of this study is to measure the SNCG and BCL6 concentrations in peripheral and menstrual fluid from endometriosis patients compared to age-matched healthy subjects or in patients after the treatment of endometriosis. The research team have the following specific objectives:
Expected Outcome and significance:
The research team expect that SNCG and BCL6 concentrations in patients with endometriosis would be significantly higher compared to age-matched healthy subjects. In addition, the investigators expect that SNCG and BCL6 concentrations may also show differences in samples of endometriosis patients treated with suppression medication or after surgery. This study aims to validate their diagnostic/prognostic potential of SNCG and BCL6 concentrations as non-invasive biomarkers for endometriosis.
STUDY DESIGN This study will focus on measuring circulatory SNCG and BCL6 concentrations in patients with endometriosis compared to age-matched healthy subjects without endometriosis. Patients with confirmed endometriosis, and the healthy control group will be recruited at TRIO Fertility following informed consent. Peripheral blood samples and menstrual samples will be collected from both groups and serum/supernatant from these samples will be used for measuring the baseline differences of SNCG and BCL6 levels. In addition, post-treatment changes in these proteins will also be measured in samples collected from endometriosis patients at the 3rd and 6th month following endometriosis suppression with dienogest, Lupron depot and addback, or Myfembree, or after laparoscopic surgery with excision or vaporization of endometriosis lesions. Analysis of circulatory SNCG/BCL6 levels will be performed using SNCG and BCL6 specific enzyme linked immunosorbent assays (ELISA), respectively, and will be compared for significant differences between the endometriosis and the control group, and pre and post treatment in endometriosis group.
This study will focus on measuring circulatory SNCG and BCL6 concentrations in patients with endometriosis compared to age-matched healthy subjects without endometriosis. Patients with confirmed endometriosis, and the healthy control group will be recruited at TRIO Fertility following informed consent.
Inclusion Criteria for Endometriosis Group:
Exclusion Criteria for Endometriosis Group:
Inclusion Criteria for Control Group:
Exclusion Criteria for Endometriosis Group:
Patients who have been diagnosed with Endometriosis
Diagnostic Test: SNCG Protein · Diagnostic Test: BCL-6 Protein
Patients who have not been diagnosed with Endometriosis
Diagnostic Test: SNCG Protein · Diagnostic Test: BCL-6 Protein
Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual.
B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centers. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis
Synuclein Gamma (SNCG) and B-cell Lymphoma 6 (BCL-6) Levels
Synuclein Gamma (SNCG) and B-cell Lymphoma 6 (BCL-6) levels (ng/ml) in serum/menstrual supernatant will be quantitated using specific ELISA kits and will be compared for significant differences in patients with endometriosis from control subjects as well as their changes before and after the treatment in endometriosis group.
Time frame: Baseline for control participants and baseline and approximately 3 months after treatment for participants with endometriosis
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — SNCG and BCL-6 levels
Supporting information: Study protocol, Informed consent form
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 11 months is below that.
Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Trio Fertility